202 related articles for article (PubMed ID: 23216269)
21. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
Chen Y; Kantarjian H; Estrov Z; Faderl S; Ravandi F; Rey K; Cortes J; Borthakur G
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):341-4. PubMed ID: 22579233
[TBL] [Abstract][Full Text] [Related]
22. Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide.
Nozzoli C; Staderini M; Veltroni A; Longo G; Bacchiarri F; Donnini I; Guarrera A; Bosi A
Leuk Lymphoma; 2015; 56(8):2388-91. PubMed ID: 25535816
[TBL] [Abstract][Full Text] [Related]
23. Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma.
Kamimura T; Miyamoto T; Yokota N; Aoki T; Ito Y; Akashi K
Intern Med; 2014; 53(15):1651-3. PubMed ID: 25088880
[TBL] [Abstract][Full Text] [Related]
24. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
Maier SK; Hammond JM
Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
[TBL] [Abstract][Full Text] [Related]
25. Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
Richardson PG; Holstein SA; Schlossman RL; Anderson KC; Attal M; McCarthy PL
Expert Opin Pharmacother; 2017 Dec; 18(18):1975-1985. PubMed ID: 29172855
[TBL] [Abstract][Full Text] [Related]
26. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Lentzsch S; O'Sullivan A; Kennedy RC; Abbas M; Dai L; Pregja SL; Burt S; Boyiadzis M; Roodman GD; Mapara MY; Agha M; Waas J; Shuai Y; Normolle D; Zonder JA
Blood; 2012 May; 119(20):4608-13. PubMed ID: 22451423
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/ refractory multiple myeloma: a real-life experience.
Soyer N; Patır P; Uysal A; Duran M; Ünal HD; Durusoy R; Tombuloğlu M; Şahin F; Töbü M; Vural F; Saydam G
Turk J Med Sci; 2018 Aug; 48(4):777-785. PubMed ID: 30119153
[TBL] [Abstract][Full Text] [Related]
28. Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales.
Brown RE; Stern S; Dhanasiri S; Schey S
Eur J Health Econ; 2013 Jun; 14(3):507-14. PubMed ID: 22572968
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
Gay F; Vincent Rajkumar S; Falco P; Kumar S; Dispenzieri A; Petrucci MT; Gertz MA; Boccadoro M; Keith Stewart A; Palumbo A
Eur J Haematol; 2010 Sep; 85(3):200-8. PubMed ID: 20477865
[TBL] [Abstract][Full Text] [Related]
30. Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
Kuroda J; Kobayashi T; Taniwaki M
Expert Rev Anticancer Ther; 2015; 15(7):787-804. PubMed ID: 25947283
[TBL] [Abstract][Full Text] [Related]
31. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
Barley K; He W; Agarwal S; Jagannath S; Chari A
Leuk Lymphoma; 2016 Nov; 57(11):2510-5. PubMed ID: 26943456
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulating drugs in myelodysplastic syndromes.
Adès L; Fenaux P
Hematology Am Soc Hematol Educ Program; 2011; 2011():556-60. PubMed ID: 22160089
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Wang M; Dimopoulos MA; Chen C; Cibeira MT; Attal M; Spencer A; Rajkumar SV; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
Blood; 2008 Dec; 112(12):4445-51. PubMed ID: 18799726
[TBL] [Abstract][Full Text] [Related]
34. A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide.
Xu G; Wang B; Yang M; Qian W
Int J Clin Exp Pathol; 2015; 8(11):15025-9. PubMed ID: 26823839
[TBL] [Abstract][Full Text] [Related]
35. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.
Biran N; Jacobus S; Vesole DH; Callander NS; Fonseca R; Williams ME; Abonour R; Katz MS; Rajkumar SV; Greipp PR; Siegel DS
Blood Cancer J; 2016 Sep; 6(9):e466. PubMed ID: 27588519
[TBL] [Abstract][Full Text] [Related]
36. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
[TBL] [Abstract][Full Text] [Related]
38. Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy.
Prebet T; Toma A; Cluzeau T; Sekeres MA; Vey N; Park S; Al Ali N; Sugrue MM; Komrokji R; Fenaux P; Gore SD
Oncotarget; 2017 Jun; 8(23):37866-37874. PubMed ID: 28184031
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
[No Abstract] [Full Text] [Related]
40. Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.
João C; Freitas J; Gomes F; Geraldes C; Coelho I; Neves M; Lúcio P; Esteves S; Esteves GV
Ann Hematol; 2016 May; 95(6):931-6. PubMed ID: 27068406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]